Global Cancer Diagnostics Partnering Deal Trends, Players, Financials and Forecasts 2010-2015

Jul 13, 2015, 12:20 ET from Research and Markets

DUBLIN, July 08, 2015 /PRNewswire/ --

Research and Markets( has announced the addition of the "Global Cancer Diagnostics Partnering 2010-2015: Deal trends, players, financials and forecasts" report to their offering.

The Global Cancer Diagnostics Partnering 2010-2015 report provides an understanding and access to the cancer diagnostics partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an understanding and analysis of how and why companies enter cancer diagnostics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors diagnostics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest cancer diagnostics agreements announced in the healthcare sectors covering the following diagnostics types:

  • Diagnostics
  • Companion
  • Imaging
  • CT
  • Endoscope
  • Molecular and nuclear
  • PET
  • MRI
  • Ultrasound
  • X ray
  • Angiography
  • Fluoroscopy
  • Mammography
  • In vitro diagnostics
  • Molecular diagnostics
  • Prognostics
  • Theranostics

Report scope:

Global Cancer Diagnostics Partnering 2010-2015 includes:

  • Trends in cancer diagnostics dealmaking in the biopharma industry since 2010
  • Analysis of cancer diagnostics deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to over 1,000 cancer diagnostics deal records
  • The leading cancer diagnostics deals by value since 2010
  • Includes companion, imaging, CT, MRI, ultrasound, in vitro, molecular, prognostics and theranostics diagnostics deals and alliances since 2010

In Global Cancer Diagnostics Partnering 2010-2015, the available deals are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific oncology therapy target
  • DIagnostics type

Key Topics Covered:

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in cancer diagnostics dealmaking

Chapter 3 Average financial deal terms for cancer diagnostics partnering

Chapter 4 Leading cancer diagnostics deals

Chapter 5 Cancer diagnostics dealmaking contracts directory

Chapter 6 Cancer diagnostics dealmaking by specific therapy type

Chapter 7 Cancer diagnostics dealmaking by specific technology type

Chapter 8 Future trends and companies in cancer diagnostics deal making

Chapter 9 Partnering resource center

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets